Unigene Laboratories Inc. (UGNE.OB) CEO Featured in Globally Distributed Biotechnology Publication
According to the National Osteoporosis Foundation, osteoporosis afflicts approximately 10 million Americans; approximately 34 million individuals have low bone mass, putting them at risk for osteoporosis. Unigene Laboratories Inc. (OTCBB: UGNE) is a biopharmaceutical company engaged in the oral and nasal administration of large-market peptide drugs. Recognizing the growing worldwide osteoporosis market, Unigene focuses on developing PTH-based therapies and calcitonin, a product for the treatment of postmenopausal osteoporosis. Today the company announced Warren P. Levy, Ph.D., CEO and president of Unigene, recently contributed a byline story in two leading pharmaceutical publications. The article, titled “Focusing on the Task of Reinventing…